Show simple item record

dc.contributor.authorZeissler, M-L
dc.contributor.authorEastwood, J
dc.contributor.authorMcCorry, K
dc.contributor.authorHanemann, Clemens Oliver
dc.contributor.authorZajicek, JP
dc.contributor.authorCarroll, Camille
dc.date.accessioned2016-07-06T17:35:10Z
dc.date.accessioned2016-07-06T17:39:33Z
dc.date.available2016-07-06T17:35:10Z
dc.date.available2016-07-06T17:39:33Z
dc.date.issued2016-06-27
dc.identifier.issn1949-2553
dc.identifier.issn1949-2553
dc.identifier.urihttp://hdl.handle.net/10026.1/5027
dc.description.abstract

Proliferator-activated receptor γ (PPARγ) activation can result in transcription of proteins involved in oxidative stress defence and mitochondrial biogenesis which could rescue mitochondrial dysfunction in Parkinson's disease (PD).The PPARγ agonist pioglitazone is protective in models of PD; however side effects have limited its clinical use. The cannabinoid Δ9-tetrahydrocannabinol (Δ9-THC) may have PPARγ dependent anti-oxidant properties. Here we investigate the effects of Δ9-THC and pioglitazone on mitochondrial biogenesis and oxidative stress. Differentiated SH-SY5Y neuroblastoma cells were exposed to the PD relevant mitochondrial complex 1 inhibitor 1-methyl-4-phenylpyridinium iodide (MPP+). We found that only Δ9-THC was able to restore mitochondrial content in MPP+ treated SH-SY5Y cells in a PPARγ dependent manner by increasing expression of the PPARγ co-activator 1α (PGC-1α), the mitochondrial transcription factor (TFAM) as well as mitochondrial DNA content. Co-application of Δ9-THC with pioglitazone further increased the neuroprotection against MPP+ toxicity as compared to pioglitazone treatment alone. Furthermore, using lentiviral knock down of the PPARγ receptor we showed that, unlike pioglitazone, Δ9-THC resulted in a PPARγ dependent reduction of MPP+ induced oxidative stress. We therefore suggest that, in contrast to pioglitazone, Δ9-THC mediates neuroprotection via PPARγ-dependent restoration of mitochondrial content which may be beneficial for PD treatment.

dc.format.extent46603-46614
dc.format.mediumPrint
dc.languageen
dc.language.isoen
dc.publisherImpact Journals, LLC
dc.relation.replaceshttp://hdl.handle.net/10026.1/5026
dc.relation.replaces10026.1/5026
dc.subjectDelta(9)-tetrahydrocannabinol
dc.subjectperoxisome proliferator-activated receptor
dc.subjectMPP+
dc.subjectmitochondrial biogenesis
dc.subjectParkinson's disease
dc.titleDelta-9-tetrahydrocannabinol protects against MPP+ toxicity in SH-SY5Y cells by restoring proteins involved in mitochondrial biogenesis
dc.typejournal-article
dc.typeJournal Article
plymouth.author-urlhttps://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000385402300134&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008
plymouth.issue29
plymouth.volume7
plymouth.publication-statusAccepted
plymouth.journalOncotarget
dc.identifier.doi10.18632/oncotarget.10314
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/Faculty of Health
plymouth.organisational-group/Plymouth/Faculty of Health/Peninsula Medical School
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA03 Allied Health Professions, Dentistry, Nursing and Pharmacy
plymouth.organisational-group/Plymouth/Research Groups
plymouth.organisational-group/Plymouth/Research Groups/FoH - Applied Parkinson's Research
plymouth.organisational-group/Plymouth/Research Groups/FoH - Community and Primary Care
plymouth.organisational-group/Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)
plymouth.organisational-group/Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CBR
plymouth.organisational-group/Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CCT&PS
plymouth.organisational-group/Plymouth/Research Groups/Plymouth Institute of Health and Care Research (PIHR)
plymouth.organisational-group/Plymouth/Users by role
plymouth.organisational-group/Plymouth/Users by role/Academics
plymouth.organisational-group/Plymouth/Users by role/Researchers in ResearchFish submission
dc.publisher.placeUnited States
dcterms.dateAccepted2016-05-09
dc.identifier.eissn1949-2553
dc.rights.embargoperiodNo embargo
rioxxterms.funderMedical Research Council
rioxxterms.identifier.projectMolecular genetic studies of iron metabolism in Parkinson's disease and related neurodegenerative disorders
rioxxterms.versionofrecord10.18632/oncotarget.10314
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2016-06-27
rioxxterms.typeJournal Article/Review
plymouth.funderMolecular genetic studies of iron metabolism in Parkinson's disease and related neurodegenerative disorders::Medical Research Council


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV